FK-506--how much potential?
FK-506 is a recently discovered immunosuppressive agent that, although structurally quite distinct from cyclosporin A (CsA), shares many of its properties. These include interference with production of interleukin 2 ( IL-2) and other lymphokines, lack of myelotoxicity and the induction of transplantation tolerance following administration of short courses to allografted rats. Compared with CsA, however, FK-506 is much more potent and the two agents can act synergistically both in vivo and in vitro. However, severe side effects of FK-506 have been reported in dogs and baboons, although not in rats. On the basis of recently published findings. Angus Thomson reviews the immunological properties of FK-506 and assesses its potential in the light of the impact already made by CsA in both the laboratory and clinic.[1]References
- FK-506--how much potential? Thomson, A.W. Immunol. Today (1989) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg
